CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors

Jianghua Wang(Huazhong Agricultural University), Baiyong Li(China National Pharmaceutical Group Corporation (China))
Cancer Immunology Immunotherapy
January 27, 2024
Cited by 19


Related Papers